Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Abalos Therapeutics

Request full access

Harnessing the power of arenaviruses in a differentiated immuno-virotherapy approach to fight cancer

Düsseldorf, GermanyFounded 2018Biotech & Life Sciences

About Abalos Therapeutics

Abalos Therapeutics GmbH is pioneering a novel approach to cancer treatment by leveraging the unique immune-stimulating properties of arenaviruses. The company operates in the biotechnology sector, focusing on developing innovative immuno-virotherapy solutions. Abalos targets cancer cells by using mammarenaviruses, which preferentially infect and proliferate within these cells, thereby inducing a robust and targeted immune response. This approach aims to activate all relevant immune cell types against both primary tumors and distant metastases.

The company's proprietary Fast Evolution Platform generates mammarenaviruses with optimized anti-tumoral properties, effectively reprogramming the immune system to eliminate malignant tumor tissue. Abalos serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, who are looking for cutting-edge cancer treatment solutions.

Abalos operates on a business model that includes research and development, clinical trials, and potential partnerships or licensing agreements with larger pharmaceutical companies. Revenue is generated through these partnerships, grants, and future sales of their therapeutic products once they receive regulatory approval.

Source: Dealroom company data

At a glance

Status
Operational
Employees
23
Open positions
None listed
Dealroom signal
69.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Medical Research, Oncology, Medical & Healthcare, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jan 2025 $0 — Coparion · Ventura BioMed Investors · Gründerfonds Ruhr · Hx Bio Ventures —
EARLY VC✓Equity / VC Feb 2024 $0 — Health for Life Capital · NRW.BANK · Boehringer Ingelheim · Coparion —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Abalos Therapeutics website traffic

Latest recorded traffic for Abalos Therapeutics is 950 monthly website visits, up 69.6% over the last three months. Abalos Therapeutics's team declined 4.2% over the past year.

Latest monthly visits950 3-month web change+69.6% 1-year team growth-4.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Abalos Therapeutics in the Düsseldorf ecosystem

Live from Dealroom

The Abalos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • Gründerfonds Ruhr
  • Boehringer Ingelheim Venture Fund
  • HTGF
  • NRW.BANK
  • Seventure Partners
  • Coparion
  • Ventura BioMed Investors
  • Hx Bio Ventures
  • Health for Life Capital
  • Boehringer Ingelheim
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany93.8%
🇦🇹 Austria6.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Abalos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Abalos Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.